PCSK9 Inhibition and Risk of Diabetes: Should We Worry?

Creative Commons License

Carugo S., Sirtori C. R., Corsini A., Tokgozoglu L., Ruscica M.

CURRENT ATHEROSCLEROSIS REPORTS, cilt.24, sa.12, ss.995-1004, 2022 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Derleme
  • Cilt numarası: 24 Sayı: 12
  • Basım Tarihi: 2022
  • Doi Numarası: 10.1007/s11883-022-01074-y
  • Dergi Adı: CURRENT ATHEROSCLEROSIS REPORTS
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, CAB Abstracts, EMBASE, MEDLINE
  • Sayfa Sayıları: ss.995-1004
  • Anahtar Kelimeler: PCSK9, New-onset diabetes, beta-cells, Evolocumab, Alirocumab, DENSITY-LIPOPROTEIN CHOLESTEROL, LOWERING GENETIC-VARIANTS, LDL-CHOLESTEROL, STATIN THERAPY, GLUCOSE-HOMEOSTASIS, INSULIN-SECRETION, SAFETY, EVOLOCUMAB, EFFICACY, ASSOCIATION
  • Hacettepe Üniversitesi Adresli: Evet

Özet

Purpose of Review Since the clinical benefit of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors occurs in a setting of reducing low-density lipoprotein-cholesterol (LDL-C) to unprecedentedly low levels, it becomes of interest to investigate possible adverse effects pertaining to the risk of new-onset diabetes (NOD).